Mount Sinai-Led Team Builds First Model of the Progression of Acute Myeloid Leukemia using CRISPR
Could Help Identify Early-Stage Therapeutic Targets
A research team led by the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) has built the first cellular model to depict the evolution of acute myeloid leukemia (AML), from its early to late stages. By using gene editing technologies to alter genes that make cells malignant, the team was able to identify potential therapeutic targets for early disease stages. The study was reported in the journal Cell Stem Cell in February.
The therapeutic targets could be applicable not just to AML but also to the blood cancer myelodysplastic syndrome and clonal hematopoiesis, which is often a preleukemic condition.
“We essentially built from scratch a model of leukemia that characterizes the molecular changes that underlie progression of the disease, and which allowed us to identify the earliest events in its development that can be therapeutically targeted,” said Eirini Papapetrou, MD, PhD, Associate Professor of Oncological Sciences at Icahn Mount Sinai, and senior author of the study. “By creating the first cellular model to track the evolution of human leukemia, we believe we’ve taken an important step toward unraveling the cellular biology of this disease. We’ve identified molecular vulnerabilities that occur early in the disease process which could potentially lead to improved biomarkers and novel treatments for AML—goals that have proven so elusive to medical science in the past.”
AML is a cancer of the blood and bone marrow, the spongy tissue inside bones where blood cells are made. The disease, which primarily affects white blood cells, is one of the most common leukemias in adults, with more than 20,000 newly diagnosed cases each year in the United States. While several new drugs have been introduced in recent years targeting the disease, they have fallen short of significantly changing patient outcomes or survival.
By introducing specific leukemia-causing gene mutations through CRISPR-mediated gene editing, Icahn Mount Sinai researchers were determined to better understand the successive stages of the evolution of leukemia. CRISPR is a powerful tool that allowed the team to alter the DNA sequences in induced pluripotent stem cells (iPSCs) to create a model with an increasing number of mutated genes that shows progressive malignant features that correspond to their human counterparts in myeloid disease. CRISPR gene editing uses Cas9, an enzyme that acts like a pair of molecular scissors with the ability to cut strands of DNA. Through use of these tools, the researchers were able to recapitulate the step-by-step conversion of a normal cell into a malignant one.
“CRISPR/Cas9 and iPSC technologies gave us the unique opportunity to characterize changes underlying the transitions between stages of AML, and to harness patterns of these changes to pinpoint target genes for early intervention,” explains Dr. Papapetrou.
Specifically, the researchers found that inflammatory and innate immunity pathways constitute such early targets and demonstrated that inhibitors of these pathways, therapies that are being trialed in blood cancers and immune-related disorders, may be promising therapeutic modalities for AML and myelodysplastic syndrome.
Other partners in the study included Memorial Sloan Kettering Cancer Center in New York, and Cincinnati Children’s Hospital Medical Center.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.
Cancer-Associated Mutations in Brain Immune Cells May Contribute to Alzheimer's Disease
Jun 11, 2026 View All Press Releases
Scientists Create Most Powerful, Accurate Tool Yet to Research Deadliest Blood Cancer
Apr 18, 2023 View All Press ReleasesScientists Create Novel Model That Shows Progression From Normal Blood Cells to Leukemia
Feb 16, 2017 View All Press Releases